[An antimetastatic study of Arg-Asp (RD) on salivary adenoid cystic carcinoma in vivo].
OBJECTIVE
To test the antimetastatic effects of Arg-Asp (RD) on salivary adenoid cystic carcinoma (SACC-LM) in vivo.


METHODS
RD was administered orally to experimental metastasized nude mice. The pulmonary metastatic foci number and survival were determined to assay the antimetastatic effects of RD.


RESULTS
30 mg/kg, 120 mg/kg of RD demonstrated an inhibitory effect on the pulmonary metastatic foci formation. All of the tested dosages (7.5 mg/kg, 30 mg/kg, 120 mg/kg) of RD prolonged the survival.


CONCLUSIONS
Oral administration of RD has a antimetastatic effect on SACC-LM. RD is low toxicity.
Li
Fenghe
F
Department of Stomatology, International Peace Hospital, Shijiazhuang 050082, China.
Yu
Guangyan
G
Li
Shenglin
S
Peng
Shiqi
S
Fu
Jia
J
Wu
Dengcheng
D
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001120:Arginine / Q000627:therapeutic use*; D001224:Aspartic Acid / Q000627:therapeutic use*; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy* / Q000517:prevention & control / Q000556:secondary; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000517:prevention & control / Q000556:secondary; D051379:Mice; D008807:Mice, Inbred BALB C; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D012468:Salivary Gland Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D001224:Aspartic Acid; D001120:Arginine; C024891:arginine aspartate